See related review by Bartels et al., <http://ccforum.com/content/17/S1/S6>

Correction
==========

Our recently published review article \[[@B1]\] contained a misprint. On page four under the sub-heading \'Goal-directed fluid therapy\' and in the third paragraph, the sentence:

\"Results of a randomized trial investigating mortality in 3,141 children with severe febrile illness and impaired perfusion in sub-Saharan Africa surprisingly showed higher mortality at 48 hours and at 4 weeks in the group that did not receive any fluid boluses compared with two groups resuscitated with albumin or saline 38.\"

should have instead read:

\"Results of a randomized trial investigating mortality in 3,141 children with severe febrile illness and impaired perfusion in sub-Saharan Africa surprisingly showed *lower*mortality at 48 hours and at 4 weeks in the group that did not receive any fluid boluses compared with two groups resuscitated with albumin or saline 38.\"

The authors sincerely regret this error.
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